Contineum Therapeutics, Inc.

CTNM Nasdaq SEC CIK 1855175
Follow Contineum Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$18.7M −46.2% vs same quarter last year
EPS, diluted −$0.49 −8.9% vs same quarter last year
Operating cash flow −$11.1M +9.3% vs same quarter last year
Operating income −$21M −40.4% vs same quarter last year
Net income by quarter
−$14.6M
−$16M
−$16M
−$12.8M
−$15.2M
−$14.5M
−$15.2M
−$18.7M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
−$75M−$50M−$25M$0$25MFY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$60M
FY24−$42.3M
FY23$22.7M
FY22-
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0$20MFY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$55.5M
FY24−$33.4M
FY23$18.9M
FY22-